🌬️ GOLD ABE Group (COPD)
GOLD 2026 ABE assessment grouping for stable COPD, combining symptom burden and exacerbation history to guide initial therapy.
From the 2023 revision the former C/D groups merged into a single high-risk group E, simplifying the matrix (original synthesis · not guideline verbatim).
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to assign group A, B, or E and select initial inhaled therapy in stable COPD.
How it works
Group E for ≥ 1 moderate exacerbation or ≥ 1 hospitalization in the past year (initial LABA+LAMA, consider ICS if eosinophils ≥ 300); otherwise group B (mMRC ≥ 2/CAT ≥ 10 → LABA+LAMA) or group A (low symptoms → single bronchodilator).
Key points
- From the 2023 revision the former C/D groups merged into a single high-risk group E, simplifying the matrix (original synthesis · not guideline verbatim).
- GOLD 2026 lowered the bar — even one moderate exacerbation places a patient in group E.
- Airflow-limitation grade (GOLD 1–4 by FEV1%) is reported separately and does not set the letter group.
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Exacerbations in the past year | None (0 moderate/severe exacerbations) |
|---|---|
| Symptom burden | mMRC 0–1 (CAT < 10) |
→GOLD groupGroup A
- Exacerbation risk：Low
- Symptoms：Low (mMRC 0–1 / CAT < 10)
| Exacerbations in the past year | ≥ 1 moderate or ≥ 1 hospitalization (severe) |
|---|---|
| Symptom burden | mMRC ≥ 2 (CAT ≥ 10) |
→GOLD groupGroup E
- Exacerbation risk：High (→ E)
- Symptoms：High (mMRC ≥ 2 / CAT ≥ 10)
Frequently asked questions
- What is GOLD ABE Group (COPD)?
- GOLD 2026 ABE assessment grouping for stable COPD, combining symptom burden and exacerbation history to guide initial therapy.
- How is GOLD ABE Group (COPD) calculated? What is the core formula?
- Group E for ≥ 1 moderate exacerbation or ≥ 1 hospitalization in the past year (initial LABA+LAMA, consider ICS if eosinophils ≥ 300); otherwise group B (mMRC ≥ 2/CAT ≥ 10 → LABA+LAMA) or group A (low symptoms → single bronchodilator).
- When is GOLD ABE Group (COPD) used?
- Use to assign group A, B, or E and select initial inhaled therapy in stable COPD.
- What are the key clinical points for GOLD ABE Group (COPD)?
- From the 2023 revision the former C/D groups merged into a single high-risk group E, simplifying the matrix (original synthesis · not guideline verbatim). GOLD 2026 lowered the bar — even one moderate exacerbation places a patient in group E. Airflow-limitation grade (GOLD 1–4 by FEV1%) is reported separately and does not set the letter group.
- What are the limits and cautions when using GOLD ABE Group (COPD)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is GOLD ABE Group (COPD) calculated in practice? Can you show a worked example?
- Inputs: Exacerbations in the past year None (0 moderate/severe exacerbations), Symptom burden mMRC 0–1 (CAT < 10) → Result: GOLD group Group A（Exacerbation risk: Low, Symptoms: Low (mMRC 0–1 / CAT < 10)） Inputs: Exacerbations in the past year ≥ 1 moderate or ≥ 1 hospitalization (severe), Symptom burden mMRC ≥ 2 (CAT ≥ 10) → Result: GOLD group Group E（Exacerbation risk: High (→ E), Symptoms: High (mMRC ≥ 2 / CAT ≥ 10)）